The aim is to discover and develop a drug that blocks a protein thought to be overactive in the disease.

Zenobia Therapeutics received an award from The Michael J. Fox Foundation for Parkinson’s Research and will be working with Christopher Ross, M.D., Ph.D., of Johns Hopkins University. The goal is to develop a neuroprotective treatment with potential to slow or stop the course of the disease.

The Therapeutics Development Initiative award will allow the research team to discover and develop compounds that block the activity of LRRK2. This protein is believed to be overactive in Parkinson’s patients.

Zenobia will use its fragment-based lead discovery expertise to identify the best candidates. The company will have access to cell assays and animal models developed in Dr. Ross’ laboratory.

Previous articleBasophil Proton Channel Implicated in Histamine Release
Next articleCelator Secures $22.5M to Advance Phase II AML Drug